Monitoring Huntington’s disease progression through preclinical and early stages

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

References

• 1  Biglan KM, Ross CA, Langbehn DR et al. Motor abnormalities in premanifest persons with Huntington’s disease: the PREDICT-HD study. Mov. Disord.24(12),1763–1772 (2009).
  MedlineGoogle Scholar
• 2  Kirkwood SC, Siemers E, Hodes ME et al. Subtle changes among presymptomatic carriers of the Huntington’s disease gene. J. Neurol. Neurosurg. Psychiatry69(6),773–779 (2000).
  Medline CASGoogle Scholar
• 3  McCusker E, Richards F, Sillence D, Wilson M, Trent RJ. Huntington’s disease: neurological assessment of potential gene carriers presenting for predictive DNA testing. J. Clin. Neurosci.7(1),38–41 (2000).
  Medline CASGoogle Scholar
• 4  Huntington Study Group. Unified Huntington’s Disease Rating Scale: reliability and consistency. Mov. Disord.11(2),136–142 (1996).
  MedlineGoogle Scholar
• 5  Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR. A new model for prediction of the age of onset and penetrance for Huntington’s disease based on CAG length. Clin. Genet.65(4),267–277 (2004).
  Medline CASGoogle Scholar
• 6  Tabrizi SJ, Reilmann R, Roos RA et al. Potential endpoints for clinical trials in premanifest and early Huntington’s disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol.11(1),42–53 (2012).▪▪ The most recent findings from TRACK-HD, reporting prospective longitudinal data on clinical and imaging findings in preclinical Huntington’s disease (HD).
  MedlineGoogle Scholar
• 7  Feigin A, Tang C, Ma Y et al. Thalamic metabolism and symptom onset in preclinical Huntington’s disease. Brain130(Pt 11),2858–2867 (2007).▪▪ Longitudinal [18F]fluorodeoxyglucose PET study of presymptomatic HD gene carriers over 4 years. Subjects also underwent concurrent MRI and [11C]raclopride PET. A thalamic metabolic compensatory mechanism was identified during the preclinical period, and a loss of this mechanism was associated with symptom onset in HD.
  Medline CASGoogle Scholar
• 8  Penney JB Jr, Young AB, Shoulson I et al. Huntington’s disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals. Mov. Disord.5(2),93–99 (1990).
  MedlineGoogle Scholar
• 9  Hogarth P, Kayson E, Kieburtz K et al. Interrater agreement in the assessment of motor manifestations of Huntington’s disease. Mov. Disord.20(3),293–297 (2005).
  MedlineGoogle Scholar
• 10  Rao AK, Muratori L, Louis ED, Moskowitz CB, Marder KS. Spectrum of gait impairments in presymptomatic and symptomatic Huntington’s disease. Mov. Disord.23(8),1100–1107 (2008).
  MedlineGoogle Scholar
• 11  Kosinski CM, Landwehrmeyer B. Huntington’s disease. In: Neurodegenerative Diseases. Neurobiology, Pathogenesis and Therapeutics. Beal MF, Lang AE, Ludolph AC (Eds). Cambridge University Press, Cambridge, UK, 847–860 (2005).
  Google Scholar
• 12  Paulsen JS, Langbehn DR, Stout JC et al. Detection of Huntington’s disease decades before diagnosis: the PREDICT-HD study. J. Neurol. Neurosurg. Psychiatry79(8),874–880 (2008).▪ Large cross-sectional MRI study demonstrating that subtle cognitive, motor, psychiatric and imaging signs can be detected one to two decades before clinical diagnosis of HD.
  Medline CASGoogle Scholar
• 13  Paulsen JS. Early detection of Huntington’s disease. Future Neurol.5(1),85–104 (2010).
  Google Scholar
• 14  Farrow M, Churchyard A, Chua P et al. Attention, inhibition, and proximity to clinical onset in preclinical mutation carriers for Huntington’s disease. J. Clin. Exp. Neuropsychol.29(3),235–246 (2007).
  MedlineGoogle Scholar
• 15  Lemiere J, Decruyenaere M, Evers-Kiebooms G, Vandenbussche E, Dom R. Cognitive changes in patients with Huntington’s disease (HD) and asymptomatic carriers of the HD mutation – a longitudinal follow-up study. J. Neurol.251(8),935–942 (2004).
  Medline CASGoogle Scholar
• 16  Solomon AC, Stout JC, Weaver M et al. Ten-year rate of longitudinal change in neurocognitive and motor function in prediagnosis Huntington disease. Mov. Disord.23(13),1830–1836 (2008).
  MedlineGoogle Scholar
• 17  Duff K, Paulsen JS, Mills JA et al. Mild cognitive impairment in Huntington’s disease. Clin. Genet.76,125 (2009).
  Google Scholar
• 18  Duff K, Paulsen JS, Beglinger LJ, Langbehn DR, Stout JC. Psychiatric symptoms in Huntington’s disease before diagnosis: the PREDICT-HD study. Biol. Psychiatry62(12),1341–1346 (2007).
  MedlineGoogle Scholar
• 19  Julien CL, Thompson JC, Wild S et al. Psychiatric disorders in preclinical Huntington’s disease. J. Neurol. Neurosurg. Psychiatry78(9),939–943 (2007).
  MedlineGoogle Scholar
• 20  Paulsen JS, Ready RE, Hamilton JM, Mega MS, Cummings JL. Neuropsychiatric aspects of Huntington’s disease. J. Neurol. Neurosurg. Psychiatry71(3),310–314 (2001).
  Medline CASGoogle Scholar
• 21  Marder K, Zhao H, Myers RH et al. Rate of functional decline in Huntington’s disease. Huntington Study Group. Neurology54(2),452–458 (2000).
  Medline CASGoogle Scholar
• 22  Puri BK, Leavitt BR, Hayden MR et al. Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial. Neurology65(2),286–292 (2005).
  Medline CASGoogle Scholar
• 23  van Vugt JP, Siesling S, Vergeer M, van der Velde EA, Roos RA. Clozapine versus placebo in Huntington’s disease: a double blind randomised comparative study. J. Neurol. Neurosurg. Psychiatry63(1),35–39 (1997).
  Medline CASGoogle Scholar
• 24  Meyer C, Landwehrmeyer B, Schwenke C et al. Rate of change in early Huntington’s disease: a clinicometric analysis. Mov. Disord.27(1),118–124 (2012).▪▪ The most recent longitudinal 3-year study of clinical measures in early HD. Linear progression was found in the Unified Huntington’s Disease Rating Scale motor score and in many of its item scores as well as other outcome measures such as the total functional capacity score.
  MedlineGoogle Scholar
• 25  Tabrizi SJ, Langbehn DR, Leavitt BR et al. Biological and clinical manifestations of Huntington’s disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol.8(9),791–801 (2009).
  MedlineGoogle Scholar
• 26  Tabrizi SJ, Scahill RI, Durr A et al. Biological and clinical changes in premanifest and early stage Huntington’s disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol.10(1),31–42 (2011).▪▪ Large multicenter longitudinal MRI study of premanifest and early HD subjects over 12 months of follow-up. Volume loss of gray matter and white matter was found and atrophy rates in these areas were also estimated. The imaging changes were further associated with changes in a broad spectrum of clinical and functional measures in the preclinical period.
  MedlineGoogle Scholar
• 27  Esmaeilzadeh M, Ciarmiello A, Squitieri F. Seeking brain biomarkers for preventive therapy in Huntington disease. CNS Neurosci. Ther.17(5),368–386 (2011).
  Medline CASGoogle Scholar
• 28  Weir DW, Sturrock A, Leavitt BR. Development of biomarkers for Huntington’s disease. Lancet Neurol.10(6),573–590 (2011).▪▪ Comprehensive review of the development of clinical, cognitive, neuroimaging and other biomarkers for HD. The implications of such scientific advances to future clinical trials are also discussed in depth.
  Medline CASGoogle Scholar
• 29  Braak H, Braak E. Allocortical involvement in Huntington’s disease. Neuropathol. Appl. Neurobiol.18(6),539–547 (1992).
  Medline CASGoogle Scholar
• 30  Vonsattel JP, Myers RH, Stevens TJ et al. Neuropathological classification of Huntington’s disease. J. Neuropathol. Exp. Neurol.44,559–577 (1985).
  Medline CASGoogle Scholar
• 31  Cha JH, Frey AS, Alsdorf SA et al. Altered neurotransmitter receptor expression in transgenic mouse models of Huntington’s disease. Philos. Trans. R. Soc. Lond. B. Biol. Sci.354(1386),981–989 (1999).
  Medline CASGoogle Scholar
• 32  Antonini A, Leenders KL, Spiegel R et al. Striatal glucose metabolism and dopamine D₂ receptor binding in asymptomatic gene carriers and patients with Huntington’s disease. Brain119(Pt 6),2085–2095 (1996).
  MedlineGoogle Scholar
• 33  Feigin A, Leenders KL, Moeller JR et al. Metabolic network abnormalities in early Huntington’s disease: an [¹⁸F]FDG PET study. J. Nucl. Med.42(11),1591–1595 (2001).
  Medline CASGoogle Scholar
• 34  Kassubek J, Juengling FD, Ecker D, Landwehrmeyer GB. Thalamic atrophy in Huntington’s disease co-varies with cognitive performance: a morphometric MRI analysis. Cereb. Cortex15(6),846–853 (2005).
  MedlineGoogle Scholar
• 35  Peinemann A, Schuller S, Pohl C et al. Executive dysfunction in early stages of Huntington’s disease is associated with striatal and insular atrophy: a neuropsychological and voxel-based morphometric study. J. Neurol. Sci.239(1),11–19 (2005).
  MedlineGoogle Scholar
• 36  Politis M, Pavese N, Tai YF et al. Hypothalamic involvement in Huntington’s disease: an in vivo PET study. Brain131(Pt 11),2860–2869 (2008).
  MedlineGoogle Scholar
• 37  Rosas HD, Salat DH, Lee SY et al. Cerebral cortex and the clinical expression of Huntington’s disease: complexity and heterogeneity. Brain131(Pt 4),1057–1068 (2008).▪ High-resolution MRI study of HD identifying widespread volume loss in multiple cortical areas. These atrophic changes outside the striatum were found to be associated with various motor, cognitive and other functional measures in this disease.
  MedlineGoogle Scholar
• 38  Rosas HD, Tuch DS, Hevelone ND et al. Diffusion tensor imaging in presymptomatic and early Huntington’s disease: selective white matter pathology and its relationship to clinical measures. Mov. Disord.21(9),1317–1325 (2006).
  MedlineGoogle Scholar
• 39  Seppi K, Schocke MF, Mair KJ et al. Diffusion-weighted imaging in Huntington’s disease. Mov. Disord.21(7),1043–1047 (2006).
  MedlineGoogle Scholar
• 40  van Oostrom JC, Dekker M, Willemsen AT et al. Changes in striatal dopamine D₂ receptor binding in pre-clinical Huntington’s disease. Eur. J. Neurol.16(2),226–231 (2009).
  Medline CASGoogle Scholar
• 41  Tang TS, Chen X, Liu J, Bezprozvanny I. Dopaminergic signaling and striatal neurodegeneration in Huntington’s disease. J. Neurosci.27(30),7899–7910 (2007).
  Medline CASGoogle Scholar
• 42  Benchoua A, Trioulier Y, Diguet E et al. Dopamine determines the vulnerability of striatal neurons to the N-terminal fragment of mutant huntingtin through the regulation of mitochondrial complex II. Hum. Mol. Genet.17(10),1446–1456 (2008).
  Medline CASGoogle Scholar
• 43  Antonini A, Leenders KL, Eidelberg D. [11C]raclopride-PET studies of the Huntington’s disease rate of progression: relevance of the trinucleotide repeat length. Ann. Neurol.43(2),253–255 (1998).
  Medline CASGoogle Scholar
• 44  Dunah AW, Jeong H, Griffin A et al.Sp1 and TAFII130 transcriptional activity disrupted in early Huntington’s disease. Science296(5576),2238–2243 (2002).
  Medline CASGoogle Scholar
• 45  Aylward EH. Change in MRI striatal volumes as a biomarker in preclinical Huntington’s disease. Brain Res. Bull.72(2–3),152–158 (2007).
  Medline CASGoogle Scholar
• 46  van Oostrom JC, Maguire RP, Verschuuren-Bemelmans CC et al. Striatal dopamine D₂ receptors, metabolism, and volume in preclinical Huntington disease. Neurology65(6),941–943 (2005).▪ Multitracer imaging study of preclinical HD gene carriers. Striatal volume loss, dopamine D2 receptor binding and metabolism were measured and compared. Among these, striatal D2 receptor binding was suggested to be the most sensitive imaging marker of preclinical HD.
  Medline CASGoogle Scholar
• 47  Weeks RA, Piccini P, Harding AE, Brooks DJ. Striatal D₁ and D₂ dopamine receptor loss in asymptomatic mutation carriers of Huntington’s disease. Ann. Neurol.40(1),49–54 (1996).
  Medline CASGoogle Scholar
• 48  Andrews TC, Weeks RA, Turjanski N et al. Huntington’s disease progression. PET and clinical observations. Brain122(Pt 12),2353–2363 (1999).
  MedlineGoogle Scholar
• 49  Ginovart N, Lundin A, Farde L et al. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington’s disease. Brain120(Pt 3),503–514 (1997).
  MedlineGoogle Scholar
• 50  Brandt J, Folstein SE, Wong DF et al. D₂ receptors in Huntington’s disease: positron emission tomography findings and clinical correlates. J. Neuropsychiatry Clin. Neurosci.2(1),20–27 (1990).
  Medline CASGoogle Scholar
• 51  Kipps CM, Duggins AJ, Mahant N et al. Progression of structural neuropathology in preclinical Huntington’s disease: a tensor based morphometry study. J. Neurol. Neurosurg. Psychiatry76(5),650–655 (2005).
  Medline CASGoogle Scholar
• 52  Pavese N, Andrews TC, Brooks DJ et al. Progressive striatal and cortical dopamine receptor dysfunction in Huntington’s disease: a PET study. Brain126(Pt 5),1127–1135 (2003).
  MedlineGoogle Scholar
• 53  Esmaeilzadeh M, Farde L, Karlsson P et al. Extrastriatal dopamine D₂ receptor binding in Huntington’s disease. Hum. Brain Mapp.32(10),1626–1636 (2011).
  MedlineGoogle Scholar
• 54  Aylward EH, Codori AM, Rosenblatt A et al. Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington’s disease. Mov. Disord.15(3),552–560 (2000).
  Medline CASGoogle Scholar
• 55  Douaud G, Gaura V, Ribeiro MJ et al. Distribution of grey matter atrophy in Huntington’s disease patients: a combined ROI-based and voxel-based morphometric study. Neuroimage32(4),1562–1575 (2006).
  Medline CASGoogle Scholar
• 56  Paulsen JS, Magnotta VA, Mikos AE et al. Brain structure in preclinical Huntington’s disease. Biol. Psychiatry59(1),57–63 (2006).
  Medline CASGoogle Scholar
• 57  Ruocco HH, Bonilha L, Li LM, Lopes-Cendes I, Cendes F. Longitudinal analysis of regional grey matter loss in Huntington disease: effects of the length of the expanded CAG repeat. J. Neurol. Neurosurg. Psychiatry79(2),130–135 (2008).
  Medline CASGoogle Scholar
• 58  Aylward EH, Nopoulos PC, Ross CA et al. Longitudinal change in regional brain volumes in prodromal Huntington disease. J. Neurol. Neurosurg. Psychiatry82(4),405–410 (2011).▪ Longitudinal MRI study of a large group of preclinical HD gene carriers and healthy controls. Atrophy rates were estimated in multiple brain regions and power and sample size calculations were performed accordingly.
  MedlineGoogle Scholar
• 59  Hobbs NZ, Henley SM, Wild EJ et al. Automated quantification of caudate atrophy by local registration of serial MRI: evaluation and application in Huntington’s disease. Neuroimage47(4),1659–1665 (2009).
  MedlineGoogle Scholar
• 60  Squitieri F, Cannella M, Simonelli M et al. Distinct brain volume changes correlating with clinical stage, disease progression rate, mutation size, and age at onset prediction as early biomarkers of brain atrophy in Huntington’s disease. CNS Neurosci. Ther.15(1),1–11 (2009).
  MedlineGoogle Scholar
• 61  Rosas HD, Liu AK, Hersch S et al. Regional and progressive thinning of the cortical ribbon in Huntington’s disease. Neurology58(5),695–701 (2002).
  Medline CASGoogle Scholar
• 62  Rosas HD, Feigin AS, Hersch SM. Using advances in neuroimaging to detect, understand, and monitor disease progression in Huntington’s disease. NeuroRx1(2),263–272 (2004).
  Medline CASGoogle Scholar
• 63  Thieben MJ, Duggins AJ, Good CD et al. The distribution of structural neuropathology in pre-clinical Huntington’s disease. Brain125(Pt 8),1815–1828 (2002).
  Medline CASGoogle Scholar
• 64  Paulsen JS, Zimbelman JL, Hinton SC et al. fMRI biomarker of early neuronal dysfunction in presymptomatic Huntington’s disease. Am. J. Neuroradiol.25(10),1715–1721 (2004).
  MedlineGoogle Scholar
• 65  Rosas HD, Hevelone ND, Zaleta AK et al. Regional cortical thinning in preclinical Huntington disease and its relationship to cognition. Neurology65(5),745–747 (2005).
  Medline CASGoogle Scholar
• 66  Hobbs NZ, Henley SM, Ridgway GR et al. The progression of regional atrophy in premanifest and early Huntington’s disease: a longitudinal voxel-based morphometry study. J. Neurol. Neurosurg. Psychiatry81(7),756–763 (2010).
  MedlineGoogle Scholar
• 67  Ciarmiello A, Cannella M, Lastoria S et al. Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington’s disease. J. Nucl. Med.47(2),215–222 (2006).
  Medline CASGoogle Scholar
• 68  Stoffers D, Sheldon S, Kuperman JM et al. Contrasting gray and white matter changes in preclinical Huntington disease: an MRI study. Neurology74(15),1208–1216 (2010).
  Medline CASGoogle Scholar
• 69  Vandenberghe W, Demaerel P, Dom R, Maes F. Diffusion-weighted versus volumetric imaging of the striatum in early symptomatic Huntington disease. J. Neurol.256(1),109–114 (2009).
  MedlineGoogle Scholar
• 70  Magnotta VA, Kim J, Koscik T et al. Diffusion tensor imaging in preclinical Huntington’s disease. Brain Imaging Behav.3(1),77–84 (2009).
  MedlineGoogle Scholar
• 71  Rosas HD, Lee SY, Bender AC et al. Altered white matter microstructure in the corpus callosum in Huntington’s disease: implications for cortical ‘disconnection’. Neuroimage49(4),2995–3004 (2010).
  MedlineGoogle Scholar
• 72  Della Nave R, Ginestroni A, Tessa C et al. Regional distribution and clinical correlates of white matter structural damage in Huntington disease: a tract-based spatial statistics study. Am. J. Neuroradiol.31(9),1675–1681 (2010).
  Medline CASGoogle Scholar
• 73  Weaver KE, Richards TL, Liang O et al. Longitudinal diffusion tensor imaging in Huntington’s disease. Exp. Neurol.216(2),525–529 (2009).
  MedlineGoogle Scholar
• 74  Bartzokis G, Lu PH, Tishler TA et al. Myelin breakdown and iron changes in Huntington’s disease: pathogenesis and treatment implications. Neurochem. Res.32(10),1655–1664 (2007).
  Medline CASGoogle Scholar
• 75  Rosas HD, Chen YI, Doros G et al. Alterations in bain transition metals in Huntington disease: an evolving and intricate story. Arch. Neurol. doi:10.1001/archneurol.2011.2945 (2012) (Epub ahead of print).
  MedlineGoogle Scholar
• 76  Nguyen T, Hamby A, Massa SM. Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington’s disease mouse model. Proc. Natl Acad. Sci. USA102(33),11840–11845 (2005).
  Medline CASGoogle Scholar
• 77  Wolf RC, Gron G, Sambataro F et al. Magnetic resonance perfusion imaging of resting-state cerebral blood flow in preclinical Huntington’s disease. J. Cereb. Blood Flow Metab.31(9),1908–1918 (2011).
  MedlineGoogle Scholar
• 78  Chen JJ, Salat DH, Rosas HD. Complex relationships between cerebral blood flow and brain atrophy in early Huntington’s disease. Neuroimage59(2),1043–1051 (2012).
  MedlineGoogle Scholar
• 79  Ma Y, Eidelberg D. Functional imaging of cerebral blood flow and glucose metabolism in Parkinson’s disease and Huntington’s disease. Mol. Imaging Biol.9(4),223–233 (2007).
  MedlineGoogle Scholar
• 80  Feigin A, Ghilardi MF, Huang C et al. Preclinical Huntington’s disease: compensatory brain responses during learning. Ann. Neurol.59(1),53–59 (2006).
  MedlineGoogle Scholar
• 81  Eidelberg D. Metabolic brain networks in neurodegenerative disorders: a functional imaging approach. Trends Neurosci.32(10),548–557 (2009).
  Medline CASGoogle Scholar
• 82  Smith Y, Raju DV, Pare JF, Sidibe M. The thalamostriatal system: a highly specific network of the basal ganglia circuitry. Trends Neurosci.27(9),520–527 (2004).
  Medline CASGoogle Scholar
• 83  Vitek JL, Giroux M. Physiology of hypokinetic and hyperkinetic movement disorders: model for dyskinesia. Ann. Neurol.47(4 Suppl. 1),S131–S140 (2000).
  Medline CASGoogle Scholar
• 84  Kassubek J, Juengling FD, Kioschies T et al. Topography of cerebral atrophy in early Huntington’s disease: a voxel based morphometric MRI study. J. Neurol. Neurosurg. Psychiatry75(2),213–220 (2004).
  Medline CASGoogle Scholar
• 85  Rosas HD, Koroshetz WJ, Chen YI et al. Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. Neurology60(10),1615–1620 (2003).
  Medline CASGoogle Scholar
• 86  Tang C, Feigin A, Bussa M et al. Identification and validation of an abnormal metabolic network associated with phenoconversion of preclinical Huntington’s disease. Neurology74(Suppl. 2),A197 (2010).
  Google Scholar
• 87  Schippling S, Schneider SA, Bhatia KP et al. Abnormal motor cortex excitability in preclinical and very early Huntington’s disease. Biol. Psychiatry65(11),959–965 (2009).
  MedlineGoogle Scholar
• 88  Orth M, Schippling S, Schneider SA et al. Abnormal motor cortex plasticity in premanifest and very early manifest Huntington disease. J. Neurol. Neurosurg. Psychiatry81(3),267–270 (2010).
  MedlineGoogle Scholar
• 89  Habeck C, Krakauer JW, Ghez C et al. A new approach to spatial covariance modeling of functional brain imaging data: ordinal trend analysis. Neural. Comp.17,1602–1645 (2005).
  MedlineGoogle Scholar
• 90  Moeller JR, Habeck CG. Reciprocal benefits of mass-univariate and bilinear modeling in brain mapping: applications to event-related functional MRI, H₂¹⁵O- and FDG-PET. Int. J. Biomed. Imaging2006,1–13 (2006).
  Google Scholar
• 91  Hauser RA, Zesiewicz TA. Clinical trials aimed at detecting neuroprotection in Parkinson’s disease. Neurology66(10 Suppl. 4),S58–S68 (2006).
  MedlineGoogle Scholar
• 92  Fang Q, Strand A, Law W et al. Brain-specific proteins decline in the cerebrospinal fluid of humans with Huntington disease. Mol. Cell. Proteomics8(3),451–466 (2009).
  Medline CASGoogle Scholar